Milestone Pharmaceuticals Inc. announced that United States Adopted Name (USAN) Council recently adopted "etripamil" as the unique non-proprietary or generic name for MSP-2017. The purpose of the United States Adopted Names Council is to serve the health professions in the United States by selecting simple, informative, and unique nonproprietary names for drugs by establishing logical nomenclature classifications based on pharmacological and/or chemical relationships. Etripamil is being developed as a patient self-administered intranasal spray to terminate paroxysmal supraventricular tachycardia (PSVT) at the onset of episodes and is currently being evaluated in a Phase 2 clinical trial (NODE-1) in the United States and Canada.

Etripamil is a novel and potent short-acting calcium channel antagonist intended for the treatment of patients with PSVT, a potentially debilitating cardiac arrhythmia. Phase 1 results showed that etripamil had a rapid onset and reached pharmacologically relevant plasma levels within 5 minutes of administration. Etripamil is designed to be short-acting and metabolized quickly after resolution of the PSVT episode to avoid the potential complications of current long-term therapies.

Etripamil is intended to address an important unmet medical need in patients who demand a convenient, rapidly efficacious and safe self-administered product for the treatment of PSVT episodes in the home setting.